This reference uses VA rating codes. For a code from a medical record, check ICD-10-CM and the service date. A clinical code alone does not establish a VA rating or a matching VA diagnostic code.
Malignant melanoma
Skin · 38 CFR § 4.118
Diagnostic Code 7833 is the VASRD entry for Malignant melanoma. VA applies the controlling criteria, shared formulas, and special instructions shown in 38 CFR Part 4. VMC presents this material for education and reference; it does not determine a Veteran's diagnosis, service connection, or evaluation.
Print the source-verified reference on this page, or choose Save as PDF in your browser’s print dialog.
Rate-under relationships
Rate under / reference DC 7800
Rate as scars (DC's 7801, 7802, 7803, 7804, or 7805), disfigurement of the head, face, or neck (DC 7800), or impairment of function (under the appropriate body system)
Rate under / reference DC 7801
Rate as scars (DC's 7801, 7802, 7803, 7804, or 7805), disfigurement of the head, face, or neck (DC 7800), or impairment of function (under the appropriate body system)
Special rating instructions
- Rate as scars (DC's 7801, 7802, 7803, 7804, or 7805), disfigurement of the head, face, or neck (DC 7800), or impairment of function (under the appropriate body system) Note: If a skin malignancy requires therapy that is comparable to that used for systemic malignancies, i.e. , systemic chemotherapy, X-ray therapy more extensive than to the skin, or surgery more extensive than wide local excision, a 100-percent evaluation will be assigned from the date of onset of treatment, and will continue, with a mandatory VA examination six months following the completion of such antineoplastic treatment, and any change in evaluation based upon that or any subsequent examination will be subject to the provisions of § 3.105(e). If there has been no local recurrence or metastasis, evaluation will then be made on residuals. If treatment is confined to the skin, the provisions for a 100-percent evaluation do not apply.
Regulatory notes
- Note: If a skin malignancy requires therapy that is comparable to that used for systemic malignancies, i.e. , systemic chemotherapy, X-ray therapy more extensive than to the skin, or surgery more extensive than wide local excision, a 100-percent evaluation will be assigned from the date of onset of treatment, and will continue, with a mandatory VA examination six months following the completion of such antineoplastic treatment, and any change in evaluation based upon that or any subsequent examination will be subject to the provisions of § 3.105(e). If there has been no local recurrence or metastasis, evaluation will then be made on residuals. If treatment is confined to the skin, the provisions for a 100-percent evaluation do not apply.
Body system and anatomy metadata
Body system: Skin
Anatomy / region tags: multi region
These tags support discovery and body-map compatibility. They do not establish Veteran-specific laterality or entitlement.
Official VA DBQ references
DBQ catalog: va-dbq-2026.09.16 · Retrieved 2026-09-16. Official VA inventory ↗
- Scars ↗ Related resourceCatalog category: Dermatological
Related by body system only. No reviewed condition-specific form match or requirement has been established.
- Skin Diseases ↗ Related resourceCatalog category: Dermatological
Related by body system only. No reviewed condition-specific form match or requirement has been established.
VA maintains some examination forms that are not available for public use. VMC does not infer a one-code-to-one-DBQ relationship.
Evidence information
When reviewing the criteria, useful evidence categories can include diagnosis and treatment records, objective testing identified by the schedule, documented frequency/duration/severity when the criteria use those concepts, and functional effects described in medical or lay evidence. The relevant evidence depends on the actual claim and medical facts.
VMC does not diagnose conditions, guarantee a percentage, or advise anyone to exaggerate symptoms.
Related diagnostic codes
Legal basis and source identification
38 CFR § 4.118 · Source current through 2026-08-06 · Verified 2026-08-10
Registry content release: vasrd-registry-2026.08.1

